GlobeNewswire: Nightstar Therapeutics plc Contains the last 10 of 30 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:56:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/06/07/1865786/0/en/Nightstar-Therapeutics-PLC-Completion-of-Acquisition-by-Biogen.html?f=22&fvtc=4&fvtv=39217Nightstar Therapeutics PLC Completion of Acquisition by Biogen2019-06-07T09:44:37Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2019/06/05/1864627/0/en/Nightstar-Therapeutics-plc-Court-Approval-Received-in-Connection-With-Acquisition-by-Biogen.html?f=22&fvtc=4&fvtv=39217Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen2019-06-05T12:33:55Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2019/05/29/1856418/0/en/Nightstar-Therapeutics-plc-Update-to-Timetable-Relating-to-the-Acquisition-by-Biogen.html?f=22&fvtc=4&fvtv=39217Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen2019-05-29T13:00:53Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2019/05/08/1819502/0/en/Nightstar-Therapeutics-PLC-Shareholders-Approve-Scheme-of-Arrangement-for-Acquisition-By-Biogen-at-General-Meeting-and-Court-Meeting-Held-on-8-May-2019.html?f=22&fvtc=4&fvtv=39217Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 20192019-05-08T13:36:26Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2019/04/26/1810278/0/en/Leading-Proxy-Advisory-Firms-ISS-and-Glass-Lewis-Recommend-Nightstar-Shareholders-Vote-FOR-Proposed-Acquisition-by-Biogen.html?f=22&fvtc=4&fvtv=39217Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar Shareholders Vote “FOR” Proposed Acquisition by Biogen2019-04-26T06:00:00Z<![CDATA[WALTHAM, Mass. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended that Nightstar shareholders vote "FOR" the proposals relating to the proposed acquisition of Nightstar by an affiliate of Biogen Inc. (“Biogen”).]]>https://www.globenewswire.com/news-release/2019/04/16/1804751/0/en/Nightstar-Therapeutics-plc-Announcement-of-Expiry-of-HSR-Waiting-Period-and-Satisfaction-of-Antitrust-Condition.html?f=22&fvtc=4&fvtv=39217Nightstar Therapeutics plc Announcement of Expiry of HSR Waiting Period and Satisfaction of Antitrust Condition2019-04-16T12:35:00Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2019/04/09/1799727/0/en/Recommended-Acquisition-of-Nightstar-Therapeutics-plc-by-Tungsten-Bidco-Limited-a-Wholly-Owned-Subsidiary-of-Biogen-Switzerland-Holdings-GmbH-Posting-of-Scheme-Document.html?f=22&fvtc=4&fvtv=39217Recommended Acquisition of Nightstar Therapeutics plc by Tungsten Bidco Limited, a Wholly-Owned Subsidiary of Biogen Switzerland Holdings GmbH; Posting of Scheme Document2019-04-09T12:55:00Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2019/03/04/1745685/0/en/Nightstar-Therapeutics-plc-reaches-agreement-to-be-acquired-by-Biogen.html?f=22&fvtc=4&fvtv=39217Nightstar Therapeutics plc reaches agreement to be acquired by Biogen2019-03-04T07:01:00Z<![CDATA[WALTHAM, Mass. and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases and Biogen Inc. ("Biogen") are pleased to announce that they have reached agreement on the terms of a recommended acquisition whereby the entire issued and to be issued share capital of Nightstar will be acquired by Tungsten Bidco Limited (a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings GmhH (“Bidder”)). It is intended that the Acquisition will be implemented by means of a U.K. Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006.]]>https://www.globenewswire.com/news-release/2018/11/13/1650095/0/en/Nightstar-Announces-Planned-Initiation-of-Phase-2-3-Expansion-Study-in-XIRIUS-Trial-for-NSR-RPGR-in-XLRP-and-Reports-Third-Quarter-2018-Financial-Results.html?f=22&fvtc=4&fvtv=39217Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results2018-11-13T06:00:00Z<![CDATA[Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders]]>https://www.globenewswire.com/news-release/2018/11/08/1647746/0/en/Nightstar-Therapeutics-to-Participate-in-Multiple-Conferences-in-November.html?f=22&fvtc=4&fvtv=39217Nightstar Therapeutics to Participate in Multiple Conferences in November2018-11-08T11:05:00Z<![CDATA[WALTHAM, Mass. and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the following investor conferences in November.]]>